Philips debuts Gyroscan CV
Philips Medical Systems has formally rolled out Gyroscan CV, the vendor’s cardiovascular MRI system. Initially highlighted at the 1998 RSNA meeting (SCAN Special Report 1/99), Gyroscan CV employs a 1.5-tesla open magnet design and features
Philips Medical Systems has formally rolled out Gyroscan CV, the vendors cardiovascular MRI system. Initially highlighted at the 1998 RSNA meeting (SCAN Special Report 1/99), Gyroscan CV employs a 1.5-tesla open magnet design and features optimized cardiovascular software, a five-element cardiac coil, and the firms EasyVision diagnostic workstation.
Gyroscan CV can provide information about cardiac anatomy and pathology; ventricular function; valvular function; wall motion, wall thickness, and thickening; myocardial perfusion; and coronary angiography, according to Philips of Best, The Netherlands. Philips believes that by using Gyroscan CV, healthcare institutions can reduce the need for x-ray and nuclear medicine scans, as well as contrast media.
One of the available options on Gyroscan CV is MobiTrak, an automated peripheral vascular angiography tool. MobiTrak, first shown at the 1996 RSNA meeting, combines contrast-enhanced 3-D MR angiography (MRA) with rapid, automatic table movement between successive coronal acquisitions. The result is high quality images from the abdominal aorta to the feet with a scan time of three to four minutes, according to Philips.
Another MRA technique, BolusTrak, provides real-time display and visual detection for contrast-enhanced procedures. With BolusTrak, the angiography acquisition can be precisely synchronized to the arrival of the bolus, according to Philips.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
